A “Scientific and commercial update” from OptiBiotix Health (OPTI). On the former, this includes on the cholesterol-reducing LPLDL that with a partner “work has been ongoing… to invest in and develop the necessary pharmaceutical processes, supporting documentation, and production batches to confirm regulatory compliance. We anticipate this work will be completed by the end of July 2019 with certification following shortly afterwards”.
Meanwhile, on ‘SlimBiome’, human study results have shown “a low glycaemic index (GI) and a low glycaemic response (GR). The results also suggest that SlimBiome when taken with a high GI sugar (e.g. sucrose) may mitigate the effect of the addition of a high GI sugar. The results of this study provide further evidence of the ability of SlimBiome to moderate blood glucose levels to increase satiety and reduce food cravings as a means of controlling the type and amount of food consumed”. On ‘SweetBiotix’, “recent studies have shown that OptiBiotix's high intensity derived sweeteners enhance the gut microbiome, significantly increasing the number and activity of bacterial species typically associated with good gut health when compared to current natural sweeteners (e.g. stevia, mogrosides)… Discussions are ongoing with another corporate partner to explore the potential to reduce the sugar, increase fibre content, and provide health benefits with a well-known branded global beverage provider”. There’s also a further commercial element to that section with SweetBiotix products now undergoing manufacturing scale up with a US corporate partner and the LPLDL partner agreement meaning that the noted work will trigger a second milestone payment to OptiBiotix – the agreement including a number of six figure payments to be made including at certain milestones and on product launch, as well as royalties on future product sales.
OptiBiotix adds it would also “allow us to market LPLDL as a product manufactured to pharmaceutical standards… opens up further opportunities with pharmaceutical companies, and creates product differentiation as the majority of probiotics are currently manufactured under food, rather than pharmaceutical standards”. Meanwhile, it emphasises current strong commercial progress, signing 16 agreements since the end of November, with products now being commercialised in over 30 countries and “as the brand value increases, this provides us with a stronger negotiating position with commercial partners… we are particularly pleased that, as the value of our brands increase internationally, we are seeing increased retail interest and a number of our larger corporate partners committing to product launches”. This provides confidence as CEO Steve O'Hara states “if most of these partners deliver on their forecasts, revenues will continue to grow in the months and years ahead”. Whilst that is safer, we believe the company should be talking about profit now – we understanding there clear scope for around a seven figure profit currently and the momentum for £7-10 million within two years.
We also note this latest announcement noting Steve Prescott, with a track record of growing probiotic sales in international markets, has commenced as CEO of the company’s ProBiotix business, and “work is ongoing to explore opportunities for a potential initial public offering of ProBiotix Health”. That looks to offer further upside from a current sub £70 million total market cap here. At up to 90p, and with a top-slice target of 125p+, buy.
This article first appeared on the N50 website which Tom Winnifrith (whose dependants are the beneficiaries of a trust which has an interest in shares in Optibiotix) runs with Steve Moore & Lucian Miers. To access the website ahead of TWO share tips from Tom & Steve at 2pm TODAY and a new shorting piece from Lucian this week click HERE
Filed under: OptiBiotix Health, Telit, FinnCap, Woodford dog, Acacia Mining, Van Elle, N50 website
RISK WARNING & DISCLAIMER - FiveFreeShareTips.com tips are provided by independent authors via a common carrier platform and do not represent the opinions of FiveFreeShareTips.com. FiveFreeShareTips.com does not accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at FiveFreeShareTips.com and via emails you receive from [email protected] are for your general information and use and are not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by the tipsters or FiveFreeShareTips.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Trading shares involves the risk of loss. The tipsters and FiveFreeShareTips.com shall not be liable for any losses or other damages incurred. The value of investments can go up or down and the past is not necessarily a guide of future performance.
Well actually it will be six. One every week day and one on Sunday, each landing with you at 11 AM sharp.
Unlike other services (which may always have a vested interest) we pride ourselves on our impartiality and cover all small caps including AIM. the Standard List, The Wider Main Market and NEX.
We cover small caps, penny shares, FTSE 350 stocks and blue chips. We look for red hot penny shares, Warren Buffett style value investments with yield and growth stocks. There is no technical analysis in our work just solid fundamental analysis from a team of experts with decades of stockmarket experience.
You will not agree with all we publish but if you are interested in small caps you cannot afford to ignore it either. Yo'll never be charged for the free share tips from Five Free Share Tips and given the star writers involved you know that they will move share prices.
There's no telephone number or postal address required and there is no charge, ever, for your Five Free Share Tips membership. Just free shares tips every day apart from Saturday And each day's share tip will not just be a few thoughts cobbled together but will be detailed analysis from experts.
Our experts do not just earn their living from writing. All own shares. If they own shares in a stock they cover they will declare it and will not sell until after advising a sell to our readers. And why not our tips are so good that why shouldn't our readers put their money where their mouth is?
Don't just take our word for it! Judge us on the calibre of our free share tips and join today to start receiving them from September 1 2017. If you don't like what you get delivered to your inbox unsubscribe and you will never hear from us again. So why not give it a go? Sign Up Now
We've put together a panel of top tipsters, including:
Tom Winnifrith, in his 27th year writing about shares, noted fraudbuster & dubbed "The maverick Tipster"
Chris Bailey, City whizz kid turned financial guru, rated as one of the top 50 commentators on shares on twitter, founder of Financial Orbit
Steve Moore, has worked with Tom Winnifrith for all bar 3 weeks of his working life - a noted commentator on value stocks
Malcolm Stacey, The Grandfather of Share Blogging, the founder of ShareCrazy & a best selling autthor of stockmarket books
Lucian Miers, the Bard of the Boleyn, one of the UK's best known short sellers
Gary Newman, writes about value investing on AIM, speciality is in share tips on oil and mining companies
Nigel Somerville, The Deputy Sheriff of AIM, an expert in forensic analysis a skill used to bust frauds but also to tip true value investments
The team from HotStockRockets, specialising in AIM and small cap shares which will fly on a three month view
Remember to book your place at the UK Investor Show 2018. The UK’s top investment show taking place on Saturday 21 April 2018 at the Queen Elizabeth II Conference Centre in Westminster, London. The show will feature a unique line-up of top speakers including Nigel Wray, tech queen Vin Murria, Dave Lenigas, Mark Slater, Tom Winnifrith, Adam Reynolds, Ed, Croft, Nick Leslau Luke Johnson and Dr Johnny Hon as well as 135 exhibiting small cap companies.
The hot share tips given here are of necessity, general. They cannot relate to the individual circumstances of investors. Anyone considering following the share tips contained here should seek independent advice from a Financial Conduct Authority authorised Stockbroker or Financial Adviser. We cannot be held liable if individuals suffer losses through following share tips contained on this site or emailed out as free share tips. The value of investments can go down as well as up. The past is not necessarily a guide to future performance. Investing in shares can lose you part or all of your capital although the potential returns are theoretically unlimited. The difference between the buy share price and the sell share price for smaller company shares (penny shares) can be significant. Profits from dealing in shares may be liable to tax - the level of tax and bases of relief from tax are subject to change. Changes in the rates of exchange may have an adverse effect on the value or price of an investment in sterling terms if it is denominated in a foreign currency. Some of the shares recommended on this site will be smaller company shares. By their nature such investments can be relatively illiquid and thus hard to trade. And that makes such investments more of a high risk than larger company shares (or 'small caps'/'penny shares'). FiveFreeShareTips.com & its sister site ShareProphets.com defines a smaller company share as any stock traded on AIM or NEX or which has a market capitalisation of less than £300 million.